相关实验视频

Updated: Jun 18, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

治疗向ERRγ通过小细胞肺癌的细胞外矩阵重塑来抑制转移

Hong Wang¹, Huizi Sun¹, Jie Huang²

¹School of Pharmaceutical Sciences, Sun Yat-sen University, 510006, Guangzhou, Guangdong, China.

EMBO molecular medicine

|July 31, 2024

概括

与雌激素相关的受体 (ERRγ) 通过重塑细胞外基质来驱动侵袭性小细胞肺癌 (SCLC) 的转移. 抑制ERRγ可以阻止SCLC的进展,并提高化疗的有效性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症转移研究癌症转移研究

背景情况:

小细胞肺癌 (SCLC) 具有高度攻击性,治疗选择差,转移频繁.
驱动SCLC转移的分子机制尚不清楚.
与雌激素相关的受体 (ERRγ) 已成为癌症进展的潜在因素.

研究的目的:

研究ERRγ在SCLC转移中的作用.
为了确定ERRγ是否是转移性SCLC的可行的治疗点.

主要方法:

在转移性SCLC瘤中分析ERRγ表达.
研究ERRγ在细胞外基质 (ECM) 重塑和细胞粘附中的功能.
在SCLC模型中利用ERRγ的遗传和药理抑制 (细胞衍生和患者衍生异体移植).
评估ERRγ抑制对瘤生长,转移和化疗反应的影响.

主要成果:

在转移性SCLC中,ERRγ过度表达,与疾病进展相关.
ERRγ直接调节参与ECM重塑和细胞粘附的关键基因,这对于转移至关重要.
抑制ERRγ显著降低了原蛋白的产生,细胞矩阵粘附和微纤维的产生.
抑制ERRγ阻断了SCLC细胞的侵入和转移,抑制了瘤的生长,并恢复了化疗的敏感性.

结论:

ERRγ是小细胞肺癌转移的关键驱动因素.
向ERRγ代表了转移性SCLC的一个有希望的治疗策略.
ERRγ抗剂可能为治疗这种致命的恶性瘤和克服治疗耐药性提供一种新的方法.

关键词:

这就是ERRgamma.细胞外矩阵重塑细胞外矩阵重塑转移转移转移转移小细胞肺癌是小细胞肺癌.治疗目标治疗目标

更多相关视频

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...